Please login to the form below

Not currently logged in
Email:
Password:

Chase Pharmaceuticals appoints former Allergan president

Douglas Ingram joins as chief executive officer
Douglas Ingram

Washington-based Chase Pharmaceuticals has appointed Douglas Ingram as its new chief executive officer to replace John Siebert, who will continue working with the company in an advisory capacity.

He brings to the role nearly 20 years of experience in biotech, pharmaceutical and medical devices leadership.

Prior to serving as president of Allergan, Ingram directed the company's operations in Europe, the Middle East and Africa and was responsible for various aspects of its global organisation including regulatory affairs and external communications.

Ingram said: “I am privileged to lead Chase Pharmaceuticals as we execute an elegant approach to the development of new Alzheimer's treatments.

“Our goal is to build a strong CNS biopharmaceutical company to improve the lives of the millions of patients and their families burdened by this devastating disease. We have an important mission and I am excited to play a leadership role in this journey.”

As CEO, Ingram will focus on the direction of Chase Pharmaceuticals' development and commercialisation of improved treatments for neurodegenerative disorders, in particular its current work on symptomatic treatment of Alzheimer's disease.

Greg Parekh, chairman of Chase Pharmaceuticals, said: “Doug has a proven track record of disruptive approaches, building strong teams and delivering above-market performance … I am confident that Doug will successfully develop Chase to its fullest potential.”

15th December 2015

From: Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics